Blood Science最新文献

筛选

英文中文

The elevation of red blood cell distribution width is an independent prognostic factor for juvenile myelomonocytic leukemia 红细胞分布宽度的升高是幼年骨髓单核细胞白血病的一个独立预后因素

Blood Science Pub Date : 2024-04-01 DOI: 10.1097/bs9.0000000000000186

Weiru Liang, Chenmeng Liu, Jingliao Zhang, M. Yi, Yuli Cai, Aoli Zhang, Lipeng Liu, Li Zhang, Xiaojuan Chen, Yao Zou, Yumei Chen, Ye Guo, Yingchi Zhang, Xiaofan Zhu, Wenyu Yang

{"title":"The elevation of red blood cell distribution width is an independent prognostic factor for juvenile myelomonocytic leukemia","authors":"Weiru Liang, Chenmeng Liu, Jingliao Zhang, M. Yi, Yuli Cai, Aoli Zhang, Lipeng Liu, Li Zhang, Xiaojuan Chen, Yao Zou, Yumei Chen, Ye Guo, Yingchi Zhang, Xiaofan Zhu, Wenyu Yang","doi":"10.1097/bs9.0000000000000186","DOIUrl":"https://doi.org/10.1097/bs9.0000000000000186","url":null,"abstract":"Juvenile myelomonocytic leukemia (JMML) is a disorder characterized by the simultaneous presence of myeloproliferative and myelodysplastic features, primarily affecting infants and young children. Due to the heterogeneous genetic background among patients, the current clinical and laboratory prognostic features are insufficient for accurately predicting outcomes. Thus, there is a pressing need to identify novel prognostic indicators. Red cell distribution width (RDW) is a critical parameter reflecting the variability in erythrocyte size. Recent studies have emphasized that elevated RDW serves as a valuable predictive marker for unfavorable outcomes across various diseases. However, the prognostic role of RDW in JMML remains unclear. Patients with JMML from our single-center cohort between January 2008 and December 2019 were included. Overall, 77 patients were eligible. Multivariate Cox proportional hazard models showed that patients with red cell distribution width coefficient of variation (RDW-CV) >17.35% at diagnosis were susceptible to much worse overall survival rate (hazard ratio [HR] = 5.22, confidence interval [CI] = 1.50–18.21, P = .010). Besides, the combination of RDW elevation and protein phosphatase non-receptor type 11 (PTPN11) mutation was likely to predict a subgroup with the worst outcomes in our cohort. RDW is an independent prognostic variable in JMML subjects. RDW may be regarded as an inexpensive biomarker to predict the clinical outcome in patients with JMML.","PeriodicalId":9049,"journal":{"name":"Blood Science","volume":"371 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140782676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum: Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia 勘误：循序渐进的治疗可提高瓦尔登斯特罗姆巨球蛋白血症患者的生存率

Blood Science Pub Date : 2024-03-07 DOI: 10.1097/BS9.0000000000000185

{"title":"Erratum: Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia","authors":"","doi":"10.1097/BS9.0000000000000185","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000185","url":null,"abstract":"In the original publication of our paper, “Sequential treatment escalation improves survival in patients with Waldenstrom mac-roglobulinemia,” published on Blood Science , 2024 Jan; 6(1): e00179, we have identified several errors that require correction. We apologize for any inconvenience caused and appreciate the opportunity to clarify the following: In Abstract, the post-relapse overall survival of patients in the escalation group and the non-escalation group (median, not reached vs. 50.7 months, respectively, P =0.039) was incorrectly reported. In Results of 3.6, the post-relapse overall survival of patients in the escalation group and the non-escalation group (median, not reached vs. 50.7 months, respectively, P =0.039) was incorrectly reported. Correction:Patients in the escalation group also had longer post-relapse overall survival compared with the non-escalation group (median, not reached vs. 50.7 months, respectively, P =0.039). The escalation group exhibited longer PFS2 (median, 50.4 months vs. 23.5 months, P <0.001) and post-relapse overall survival time (median, not reached vs. 50.7 months, respectively, P =0.039) than the non-escalation group (Figure 6A–B). These corrections do not significantly impact the overall findings and conclusions of the paper. We would like to assure readers that the corrected values do not alter the interpretations or validity of the research.","PeriodicalId":9049,"journal":{"name":"Blood Science","volume":"41 15","pages":"e00185 - e00185"},"PeriodicalIF":0.0,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140076984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0